Christopher P. Cannon
Brigham and Women's Hospital
Internal medicineSurgeryCardiologyRandomized controlled trialIntensive care medicineAspirinAcute coronary syndromeUnstable anginaClopidogrelTIMIHeart failureCoronary artery diseaseThrombolysisPercutaneous coronary interventionIn patientMyocardial infarctionStrokeDiabetes mellitusMedicine
Publications 1316
#1Kazuma Oyama (Brigham and Women's Hospital)H-Index: 3
#2Robert P. Giugliano (Brigham and Women's Hospital)H-Index: 91
Last. Eugene Braunwald (Brigham and Women's Hospital)H-Index: 266
view all 8 authors...
Abstract Background The 2018 U.S. cholesterol management guideline recommends additional lipid-lowering therapy with ezetimibe for secondary prevention in very high-risk patients with low-density l...
1 CitationsSource
#1Jorge Plutzky (Brigham and Women's Hospital)H-Index: 72
#2Mark D. Benson (Brigham and Women's Hospital)H-Index: 11
Last. Anton Dodek (Blue Cross Blue Shield of Massachusetts)H-Index: 4
view all 14 authors...
Abstract null null Background null Implementation of guideline-directed cholesterol management remains low despite definitive evidence establishing their reduction of cardiovascular (CV) events, especially in high atherosclerotic CV disease (ASCVD) risk patients. Modern electronic resources now exist that may help improve health care delivery. While electronic medical records (EMR) allow for population health screening, the potential for coupling EMR screening to remotely delivered algorithmic p...
#1Uwe ZeymerH-Index: 72
#2Orly LeivaH-Index: 8
Last. Christopher P. CannonH-Index: 168
view all 16 authors...
Aims To investigate the safety and efficacy of dabigatran dual therapy (110 or 150 mg twice daily, plus clopidogrel or ticagrelor) vs warfarin triple therapy in patients with atrial fibrillation undergoing PCI for ST elevation myocardial infarction (STEMI). Methods and results In RE-DUAL PCI, 305 patients with STEMI were randomised to dabigatran 110 mg (n=113 versus 106 warfarin) or 150 mg (n=86 versus 84 warfarin). Primary endpoint was time to first major or clinically relevant non-major bleedi...
1 CitationsSource
#1Gorav Batra (Uppsala University)H-Index: 5
#2Tatevik Ghukasyan Lakic (Uppsala University)H-Index: 4
Last. Emil Hagström (Uppsala University)H-Index: 28
view all 13 authors...
Importance null Inflammation promotes cardiovascular disease and anti-inflammatory treatment reduces cardiovascular events in patients with chronic coronary syndrome. Chronic kidney disease (CKD) is a risk factor for cardiovascular disease. It is unclear how inflammation mediated by interleukin 6 (IL-6) in patients with CKD is linked to cardiovascular disease. null Objective null To investigate associations between IL-6 and cardiovascular outcomes in patients with chronic coronary syndrome in as...
#1Brendon L. Neuen (The George Institute for Global Health)H-Index: 11
#2Megumi Oshima (Kanazawa University)H-Index: 7
Last. José Luis Górriz (University of Valencia)H-Index: 27
view all 19 authors...
Aims null Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal use of agents that block the renin-angiotensin-aldosterone system, particularly in patients with chronic kidney disease (CKD). In patients with CKD, sodium‒glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection, but whether they affect the risk of hyperkalaemia remains uncertain. null Methods and results null The CREDENCE trial randomized 4401 participants with T2DM and C...
3 CitationsSource
#1Suzanne V. Arnold (UMKC: University of Missouri–Kansas City)H-Index: 41
#2Christopher P. Cannon (Brigham and Women's Hospital)H-Index: 168
Last. Mikhail Kosiborod (The George Institute for Global Health)H-Index: 64
view all 11 authors...
Background Because of an increasing number and complexity of treatment options for lipid-lowering therapy in patients with atherosclerotic cardiovascular disease, guidelines recommend greater active involvement of patients in shared decision-making. However, patients' understanding and perceptions of the benefits, risks, and treatment objectives of lipid-lowering therapy are unknown. Methods and Results Structured questionnaires were conducted in 5006 US outpatients with atherosclerotic cardiova...
#1Adam N Berman (Brigham and Women's Hospital)H-Index: 4
#2David W. Biery (Brigham and Women's Hospital)H-Index: 9
Last. Ron Blankstein (Brigham and Women's Hospital)H-Index: 77
view all 16 authors...
2 CitationsSource
#1Clare Arnott (The George Institute for Global Health)H-Index: 11
#2Jingwei Li (The George Institute for Global Health)H-Index: 10
Last. KW Mahaffey (Janssen Pharmaceutica)H-Index: 4
view all 19 authors...
Heart failure is prevalent in those with type 2 diabetes and chronic kidney disease and is associated with significant mortality and morbidity. In the CREDENCE trial canagliflozin reduced the risk of hospitalization for heart failure (HHF) or cardiovascular (CV) death by 31%. In this current analysis we sought to determine whether the effect of canagliflozin on HHF/CV death differed in subgroups defined by key baseline participant characteristics. Cox regression models were used to estimate haza...
1 CitationsSource
Background null In the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure) trial, sotagliflozin, a sodium-glucose cotransporter-1 and sodium-glucose cotransporter-2 inhibitor, reduced total occurrences of cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure relative to placebo by 33%. null Objective null To determine whether sotagliflozin increased the prespecified efficacy outcome ...
Abstract null null Background null Low-density lipoprotein cholesterol (LDL-C) is associated with heightened risk of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in peripheral artery disease (PAD). Lipid-lowering therapies (LLT) that reduce LDL-C decrease this risk. null null null Objectives null The authors examined LLT use and actual achieved LDL-C in PAD. null null null Methods null PAD patients in MarketScan from 2014 to 2018 were identified. Outcomes inclu...
2 CitationsSource